Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT05879822 |
TitleA Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive | Phase
Phase 2
|
Date Added 2023-05-30 |
Location
Brazil
China Georgia Greece Hungary New Zealand Romania South Africa Turkey |
Prior IO Allowed No |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
INCB099280 |
Tags
MSI-H/ MMRd
|
| NCT ID NCT05865535 |
TitleA Dose Escalation Study of AV-380 in Metastatic Cancer Patients With Cachexia | Phase
Phase 1
|
Date Added 2023-05-19 |
Location
California, United States
Florida, United States Georgia, United States Nebraska, United States New York, United States Oregon, United States South Carolina, United States Tennessee, United States Texas, United States |
Prior IO Allowed No |
CRC-directed No |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05838768 |
TitleStudy of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency. | Phase
Phase 1
|
Date Added 2023-05-03 |
Location
California, United States
Massachusetts, United States New York, United States Texas, United States Belgium China France Germany Israel Italy Japan Korea, Republic of Norway Singapore Spain Sweden Taiwan United Kingdom |
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
HRO761, Irinotecan |
Tags
MSI-H/ MMRd
|
| NCT ID NCT05799443 |
TitleEfficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer | Phase
Phase 2
|
Date Added 2023-04-05 |
Location |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs
cetuximab, Irinotecan Hydrochloride, Tislelizumab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05798533 |
TitleNeo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03) | Phase
Phase 1
|
Date Added 2023-04-04 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Cyclophosphamide, Fludarabine, Interleukin-2 |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05785325 |
TitleRC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer | Phase
Phase 2
|
Date Added 2023-03-27 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
RC48-ADC plus Bevacizumab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05784688 |
TitleStudy of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | Phase
Phase 1, Phase 2
|
Date Added 2023-03-27 |
Location
Texas, United States
Washington, United States Korea, Republic of |
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
TU2218 + Pembrolizumab |
Tags
MSS/ MMRp
|
| NCT ID NCT05783089 |
TitleMSLN-targeted CAR-T Cells in Solid Tumors. | Phase
Phase 1
|
Date Added 2023-03-24 |
Location |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05771181 |
TitleVitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients | Phase
Phase 2
|
Date Added 2023-03-16 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs
Fruquintinib, Tislelizumab, Vitamin E |
Tags
MSS/ MMRp
|
| NCT ID NCT05770102 |
TitleDETERMINE Trial Treatment Arm 2: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition | Phase
Phase 2
|
Date Added 2023-03-15 |
Location
United Kingdom
|
Prior IO Allowed No |
CRC-directed No |
Status
Recruiting
|
Drugs
Atezolizumab |
Tags
MSI-H/ MMRd
|
